Project Grant R01CA290796
Award Date
1/3/25
Completion Date
12/31/29
Dollars Obligated
$436K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Baltimore, MD 21201, USA
Similar Awards
This $465,020 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Maryland, Baltimore to investigate how chemotherapy used to treat ovarian cancer can inadvertently stimulate tumor-associated enzymes that promote metastasis. The goal is to determine the specific mechanisms by which chemotherapy activates these enzymes, in order to develop strategies to neutralize the pro-metastatic effects. The 5-year research...
This $473,100 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research by the University of Maryland, Baltimore to investigate the role of neddylation in the repair of topoisomerase I inhibitor-induced replication damage in colorectal cancer. The research aims to assess the combination of the topoisomerase I inhibitor irinotecan and the NEDD8-activating enzyme inhibitor pevonedistat in colorectal cancer preclinical models,...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $150,271 to the University of Maryland Baltimore County (UMBC) to investigate the role of the protein kinase ADCK5 in ovarian cancer. The 2-year project, which began on September 20, 2023, aims to gain fundamental insights into the mechanisms underlying ovarian cancer, the most lethal gynecologic malignancy in the United States. The research seeks to identify potential new...
The National Cancer Institute (NCI) awarded a $408,829 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of Pittsburgh to develop positive allosteric modulators (PAMs) targeting the XCR1 chemokine receptor. This research aims to enhance the function of conventional dendritic cells type 1 (cDC1s) and cytotoxic T-cell responses within the tumor microenvironment as a novel approach for cancer treatment. The project will utilize DNA-encoded library technology to screen for...
The National Cancer Institute (NCI) awarded a $619,294 Project Grant under CFDA 93.394 "Cancer Detection and Diagnosis Research" to the University of California, San Diego (UCSD) to develop slow-release CPMV (Cowpea Mosaic Virus)-polymer blend formulations for intratumoral immunotherapy delivery. The project aims to formulate CPMV-laden slow-release devices, establish and tune the release rates, confirm the structural integrity and biological activity of the released CPMV, and...
This federal Project Grant award of $400,000.00 was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to Nuago Therapeutics Inc., a small disadvantaged business located in Chicago, IL. The funding supports the development of a short RNA therapeutic to treat ovarian cancer. The project aims to advance targeted cancer therapies, which have struggled to produce cures for solid cancers, through this innovative approach. The award period runs from June 9, 2025 to May...
The National Cancer Institute (NCI) awarded a $483,556 Project Grant (CFDA 93.395 - Cancer Treatment Research) to the University of New Mexico Health Sciences Center (UNM HSC) to investigate the use of toll-like receptor (TLR) agonist-modified mesoporous silica nanoparticles (MSN) for the treatment of peritoneal metastases in ovarian and colorectal cancers. The project aims to define the mechanisms by which intraperitoneal delivery of the modified-MSN leads to tumor eradication, focusing on...
The National Cancer Institute (NCI) awarded a $399,214 Project Grant under CFDA 93.395 - Cancer Treatment Research to Proton Bio, Inc., a minority-owned business located in Baltimore, Maryland. The grant supports a 12-month project to develop and evaluate a novel therapy targeting the proton-sensing receptor GPR68 as a potential treatment for glioblastoma (GBM), the most common and aggressive form of adult brain cancer. The project will focus on three key objectives: 1) define the in vitro...
The National Cancer Institute (NCI) awarded the University of Alabama at Birmingham (UAB) a $585,228 Project Grant (CFDA 93.395 - Cancer Treatment Research) to develop a novel antibody-drug conjugate (ADC) platform. The grant, titled "The Resurgence of Antibody-Drug Conjugates via PMPC-Polymer Engineering," aims to enhance the anti-cancer efficacy and overcome the limitations of existing ADCs. The key products and services to be delivered under this 5-year grant include: Confirming the...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Luminary Therapeutics, Inc., a self-certified small disadvantaged business, to develop an innovative chimeric antigen receptor (CAR) T-cell therapy targeting epithelial ovarian carcinoma. The $798,512 award, with a project period from September 2024 to August 2025, supports the development of an "armored split CAR" T-cell product that combines two CAR molecules...